Company news

Cipher Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

May 10, 2019

Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

May 1, 2019

Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors

March 26, 2019

Cipher Pharmaceuticals Announces Change to Management Team

March 20, 2019

Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

March 19, 2019

Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

March 15, 2019

Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada

December 18, 2018

Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

December 17, 2018

Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018

December 5, 2018

Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations

December 4, 2018

Cipher Pharmaceuticals Reports Q3 2018 Results

November 7, 2018

Notice of Cipher Pharmaceuticals Q3 2018 Conference Call

October 24, 2018

Cipher Pharmaceuticals Announces Canadian Launch of Brinavess® (vernakalant hydrochloride)

October 24, 2018

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis

September 18, 2018

Cipher Pharmaceuticals Receives Health Canada Approval of Xydalba(TM) (dalbavancin hydrochloride)

September 10, 2018

Cipher Pharmaceuticals Reports Q2 2018 Results

August 10, 2018

Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica®

July 30, 2018

Notice of Cipher Pharmaceuticals Q2 2018 Conference Call

July 23, 2018

Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs

June 6, 2018

Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.

May 16, 2018

Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma

May 15, 2018

Cipher Pharmaceuticals Reports Q1 2018 Results

May 10, 2018

Notice of Cipher Pharmaceuticals Q1 2018 Conference Call & Annual Meeting

May 1, 2018

Cipher Pharmaceuticals Proposes Adding Dr. Laurence Terrisse-Rulleau To Board of Directors

April 26, 2018

Cipher Pharmaceuticals to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference

April 24, 2018

Cipher Pharmaceuticals Provides Corporate Update and Preliminary Q1 2018 Revenue Results

April 23, 2018

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics

April 6, 2018

Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

March 20, 2018

Cipher Pharmaceuticals Reports Q4 & FY2017 Results

February 28, 2018

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® from Synergy Pharmaceuticals

February 28, 2018

Notice of Cipher Pharmaceuticals Q4 and Year-End 2017 Conference Call

February 9, 2018

Cipher Pharmaceuticals and Italmex Pharma Announce Exclusive Distribution Agreement for Isotretinoin Product in Mexico

January 9, 2018

Cipher Pharmaceuticals Announces Canadian Launch of OZANEX(TM) (ozenoxacin cream 1%), a Novel Topical Antibiotic

January 8, 2018

Cipher Pharmaceuticals Announces New Credit Facility

November 3, 2017

Cipher Pharmaceuticals Reports Q3 2017 Operating & Financial Results

November 3, 2017

/C O R R E C T I O N from Source -- Cipher Pharmaceuticals Inc./

October 17, 2017

Cipher Pharmaceuticals Comments on Supply Chain Impact from Hurricane Maria

October 10, 2017

Cipher Pharmaceuticals Comments on FDA Warning Letter for ConZip® (Tramadol)

September 7, 2017

Cipher Pharmaceuticals reports Q2 2017 financial results

August 11, 2017

Notice of Cipher Pharmaceuticals Q2 2017 Conference Call

July 25, 2017

Cipher Pharmaceuticals Adds New Vice President of Corporate Development

June 2, 2017

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders

May 12, 2017

Cipher Pharmaceuticals reports Q1 2017 financial results

May 11, 2017

Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX(TM) (ozenoxacin cream 1%)

May 8, 2017

Cipher Pharmaceuticals Announces Sale of U.S. Commercial Assets to EPI Group

May 1, 2017

Notice of Cipher Pharmaceuticals Q1 2017 Conference Call & Annual Meeting

April 27, 2017

Cipher Pharmaceuticals Proposes Adding Robert Tessarolo and Arthur Deboeck to Board of Directors

April 12, 2017

Cipher Pharmaceuticals announces amendment to debt agreement and partial prepayment

April 3, 2017

Cipher Pharmaceuticals Appoints Robert D. Tessarolo as CEO

March 20, 2017

Cipher Pharmaceuticals Reports 2016 Q4 & Year-End Financial Results

March 2, 2017

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks